<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interstitial lung disease in rheumatoid arthritis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interstitial lung disease in rheumatoid arthritis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interstitial lung disease in rheumatoid arthritis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fiona R Lake, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joyce S Lee, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul F Dellaripa, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interstitial lung disease (ILD) is the most common manifestation of rheumatoid lung disease [
         <a href="#rid1">
          1,2
         </a>
         ]. However, rheumatoid arthritis-associated ILD (RA-ILD) is not a single pathologic diagnosis, but rather presents with a variety of clinical, radiographic, and pathologic features that impact the natural history, response to treatment, and long-term prognosis.
        </p>
        <p>
         ILD complicating rheumatoid arthritis (RA) will be reviewed here. Other pulmonary complications associated with RA and their management are discussed separately  (
         <a class="graphic graphic_table graphicRef71641" href="/z/d/graphic/71641.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef65141" href="/z/d/graphic/65141.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         As RA-ILD is often asymptomatic, the reported frequency depends upon the type of investigation used and the severity of RA in the population studied [
         <a href="#rid3">
          3-10
         </a>
         ]. The following observations illustrate the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a database study that examined insurance claims from 2003 to 2014, the prevalence of RA-ILD ranged from 3.2 to 6.0 cases per 100,000, and the incidence ranged from 2.7 to 3.8 per 100,000 [
         <a href="#rid11">
          11
         </a>
         ]. The prevalence increased over time, while the incidence remained stable. The median survival was 7.8 years (95% CI 7.1-8.3).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically significant RA-ILD occurs in nearly 10 to 15 percent of patients with RA [
         <a href="#rid9">
          9,12,13
         </a>
         ] and is generally more common among men with RA than women [
         <a href="#rid9">
          9,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with early rheumatoid disease (joint symptoms &lt;2 years) who were surveyed with a range of investigations including pulmonary function tests (PFTs), chest radiographs, and bronchoalveolar lavage (BAL), 21 of 36 patients (58 percent) had abnormal findings on at least one modality that were consistent with ILD [
         <a href="#rid5">
          5
         </a>
         ]. Among these patients, pulmonary involvement was clinically apparent in 14 percent and clinically silent in 44 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series, the prevalence of changes characteristic of idiopathic pulmonary fibrosis (IPF)on high-resolution computed tomography (HRCT), regardless of pulmonary symptoms, abnormal lung function, or the duration of the rheumatoid disease, was nearly 20 percent [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An autopsy study of 81 patients with longstanding RA noted that 28 (35 percent) had evidence of ILD, and in seven (9 percent), the cause of death was respiratory failure related to ILD [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Disease-modifying antirheumatic drugs (DMARDs) and biologic therapies have reduced the extra-articular manifestations of RA, but their impact on RA-ILD is not clear. Case reports, series, and data from registries demonstrate a spectrum of pulmonary effects, including development of new ILD, worsening of preexisting ILD, and resolution of ILD.
        </p>
        <p>
         In an analysis of data from the British Society for Rheumatology Biologics Register, outcomes of anti-tumor necrosis factor-alpha (TNF-alpha) therapy were compared with DMARDs in patients with known RA-ILD [
         <a href="#rid15">
          15
         </a>
         ]. After adjustment for age, sex, and other potential confounders, the adjusted mortality rate ratio was 0.81 (95% CI 0.38-1.73) for the anti-TNF-alpha cohort compared with the DMARD cohort, suggesting that anti-TNF-alpha agents did not increase mortality. However, RA-ILD was a more common cause of death in the anti-TNF cohort. At this stage, it is not clear what the overall impact of biologic agents is on morbidity or mortality from ILD [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          RISK FACTORS AND GENETIC PREDISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for RA-ILD include more severe RA, high C-reactive protein, male sex, older age, obesity, cigarette smoking, severe extra-articular disease, and exposure to fine particulate matter [
         <a href="#rid13">
          13,18-22
         </a>
         ]. The principal
         <strong>
          preventable
         </strong>
         risk factor for ILD is cigarette smoking [
         <a href="#rid7">
          7,23
         </a>
         ]. One study of 336 patients with RA found that those with a &gt;25 pack-year smoking history were significantly more likely to have radiographic evidence of ILD (odds ratio [OR] 3.76, 95% CI 1.59-8.88) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serologic features
         </strong>
         – Serologic studies, such as a high titer of rheumatoid factor (RF)(eg, ≥90 international units/mL), may identify patients at higher risk of ILD [
         <a href="#rid10">
          10,20
         </a>
         ]. While a higher titer of anti-cyclic citrullinated peptide (anti-CCP) antibodies is also a risk factor for ILD, the presence of these antibodies more strongly predicts RA-associated airway disease [
         <a href="#rid24">
          24
         </a>
         ]. Certain subtypes of anti-CCP antibodies (eg, Hsp90) may be more specific markers for ILD. (See
         <a class="local">
          'Experimental serum markers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cigarette smoking
         </strong>
         <strong>
          and environmental exposures
         </strong>
         – Lung injury from cigarette smoking and other stimuli may contribute to the posttranslational modification (citrullination) of proteins, followed by an autoimmune response [
         <a href="#rid25">
          25
         </a>
         ]. Higher levels of a variety of specific anti-citrullinated peptide antibodies (ACPAs) and an expanded repertoire of these antibodies were present in patients with RA-ILD and lung function abnormalities [
         <a href="#rid26">
          26
         </a>
         ]. RA-associated antibodies have also been found in the sputum of patients at risk of RA well before joint disease developed [
         <a href="#rid27">
          27,28
         </a>
         ]. This is an area of active research. (See
         <a class="medical medical_review" href="/z/d/html/7513.html" rel="external">
          "Pathogenesis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic risk factors
         </strong>
         – The gain-of-function
         <em>
          MUC5B
         </em>
         promoter variant rs35705950 is the strongest risk factor for development of idiopathic pulmonary fibrosis (IPF); among patients with RA, this variant is associated with an increased risk for RA-ILD (adjusted OR 3.1; 95% CI 1.8-5.4), a higher lifetime risk of RA-ILD (17 versus 6 percent) and increased risk of RA-ILD development within two years of RA diagnosis (adjusted OR 3.3; 95% CI 2.0-5.6) [
         <a href="#rid29">
          29-31
         </a>
         ]. Additionally, in patients with RA-ILD, the
         <em>
          MUC5B
         </em>
         variant is associated with features of usual interstitial pneumonia (UIP) on high-resolution CT (HRCT). The exact role of
         <em>
          MUC5B
         </em>
         protein in the pathogenesis of fibrotic lung disease is not known, but accumulation of
         <em>
          MUC5B
         </em>
         may disrupt repair mechanisms or interfere with ciliary clearance. This
         <em>
          MUC5B
         </em>
         variant has not been associated with ILD in systemic sclerosis or inflammatory myositis, underscoring the similarity of RA-ILD to IPF. In IPF, presence of the
         <em>
          MUC5B
         </em>
         variant has been associated with significantly better survival [
         <a href="#rid32">
          32
         </a>
         ]. By contrast, the
         <em>
          MUC5B
         </em>
         promoter variant did not affect transplant-free survival in 261 patients with RA-ILD [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis", section on 'MUC5B'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Genome-wide association studies have also identified other variants associated with ILD development in patients with RA, such as
         <em>
          PPFIBP2
         </em>
         [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2151942884">
         <span class="h1">
          PATHOLOGIC PATTERNS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A spectrum of lung pathology is seen in RA-ILD, with the lung histopathologic features generally resembling those of idiopathic interstitial pneumonias  (
         <a class="graphic graphic_table graphicRef68251" href="/z/d/graphic/68251.html" rel="external">
          table 3
         </a>
         ). However, the presence of RA as an underlying driver of pulmonary pathology alters the epidemiology, natural history, and treatment of patients with these pathologic patterns compared with those of patients with idiopathic disease. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
         As practice has evolved in the direction of less frequent lung biopsy, pathologic patterns are now more frequently inferred from radiographic features. (See
         <a class="local">
          'Imaging'
         </a>
         below.)
        </p>
        <p>
         The most common histopathologic patterns seen in RA-ILD are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP) [
         <a href="#rid18">
          18,35-41
         </a>
         ]. Differences in the pathological picture of the idiopathic and RA-associated UIP picture have been noted, with fewer fibroblastic foci in RA [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p>
         The full spectrum of histopathologic patterns of ILD associated with RA include [
         <a href="#rid35">
          35-41,43,44
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NSIP  (
         <a class="graphic graphic_picture graphicRef75438" href="/z/d/graphic/75438.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef58583" href="/z/d/graphic/58583.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         UIP  (
         <a class="graphic graphic_picture graphicRef58242" href="/z/d/graphic/58242.html" rel="external">
          picture 3
         </a>
         ), which is the pattern associated with idiopathic pulmonary fibrosis (IPF) in patients without underlying connective tissue disease. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Usual interstitial pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organizing pneumonia  (
         <a class="graphic graphic_picture graphicRef72270" href="/z/d/graphic/72270.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef60476" href="/z/d/graphic/60476.html" rel="external">
          picture 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoid interstitial pneumonia  (
         <a class="graphic graphic_picture graphicRef64424" href="/z/d/graphic/64424.html" rel="external">
          picture 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Desquamative interstitial pneumonia (DIP)  (
         <a class="graphic graphic_picture graphicRef58789" href="/z/d/graphic/58789.html" rel="external">
          picture 7
         </a>
         ). DIP is most commonly associated with cigarette smoking, but rare cases have been reported in RA in the absence of smoking [
         <a href="#rid39">
          39,45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Desquamative interstitial pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse alveolar damage, which is the pathologic correlate of acute interstitial pneumonia  (
         <a class="graphic graphic_picture graphicRef53033" href="/z/d/graphic/53033.html" rel="external">
          picture 8
         </a>
         and
         <a class="graphic graphic_picture graphicRef63702" href="/z/d/graphic/63702.html" rel="external">
          picture 9
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleuroparenchymal fibroelastosis (PPFE). PPFE is characterized by bilateral subpleural fibrosis and pleural thickening, predominantly affecting the upper lobes, and is rare in RA [
         <a href="#rid47">
          47-49
         </a>
         ]. The diagnosis is often a clinical one, made on the basis of definite or consistent features on high-resolution CT (HRCT). (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Idiopathic pleuroparenchymal fibroelastosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In some patients, a combination of histopathologic types may be present, in which case a determination of the dominant type may be made to assist in treatment decisions.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In RA-ILD, the onset of symptoms is typically around 50 to 60 years of age [
         <a href="#rid14">
          14,35,50
         </a>
         ]. Males with RA are two to three times more likely to acquire ILD than females. While RA-ILD is often associated with erosive joint disease and postdates the onset of joint symptoms by up to five years, it can occasionally precede joint disease [
         <a href="#rid18">
          18
         </a>
         ]. Subclinical or preclinical interstitial changes may also be seen on incidental chest imaging, and have been associated with male sex, later onset of RA,
         <em>
          MUC5B
         </em>
         promoter variant rs35705950, and increased disease activity [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
         The exact clinical presentation of RA-associated ILD depends in part on the underlying lung pathology. Most often, symptoms develop insidiously and include dyspnea on exertion and a nonproductive cough. Recognition of exertional dyspnea may be delayed due to the exercise limitation associated with joint disease. Less common manifestations include fever and chest pain.
        </p>
        <p>
         Patients with the pathologic pattern of usual interstitial pneumonia (UIP) typically become symptomatic late in its course when widespread fibrosis is present. By contrast, a fulminant onset has been described in a few cases of rapidly fatal Hamman-Rich type syndrome, which has the pathologic pattern of acute interstitial pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Classification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)"
         </a>
         .)
        </p>
        <p>
         Physical signs may be absent in early RA-ILD disease. Bibasilar crackles are present in over 75 percent, while signs of pulmonary hypertension and respiratory failure may develop late in the course of disease [
         <a href="#rid35">
          35,50
         </a>
         ]. Clubbing is frequently noted in patients with the UIP pattern of RA-ILD (&gt;75 percent), but is much less common among those with other patterns of RA-ILD [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         RA-ILD is usually suspected when a patient with RA develops dyspnea, cough, auscultatory crackles, or abnormalities on pulmonary function tests (PFTs) or chest imaging. The evaluation of suspected RA-ILD typically includes a combination of laboratory testing, PFTs, imaging, and sometimes bronchoalveolar lavage (BAL), but uncommonly a lung biopsy. These tests are designed to characterize the presence, pattern, and severity of ILD, and also to exclude alternative diagnoses. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3950336670">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected RA-ILD based on clinical evaluation should receive chest imaging for further evaluation. All of the radiographic patterns seen in idiopathic ILD can occur in the context of RA  (
         <a class="graphic graphic_table graphicRef68251" href="/z/d/graphic/68251.html" rel="external">
          table 3
         </a>
         ). For patients with a known diagnosis of RA, if there is a compatible high-resolution CT (HRCT) scan showing fibrotic ILD, further identification of usual interstitial pneumonia (UIP) or non-UIP lung disease is not pursued as the therapeutic approach for UIP and non-UIP fibrotic RA-ILD is the same. In addition, patterns suggesting organizing pneumonia, nonfibrotic nonspecific interstitial pneumonia (NSIP), or lymphoid interstitial pneumonia are typically treated without pathologic confirmation.
        </p>
        <p>
         In a minority of cases, when the clinical and HRCT features are discordant or atypical, the patient is symptomatic and fit for surgery, and the biopsy would change the therapeutic approach (eg, treatment of an underlying infection or use of glucocorticoids for organizing pneumonia), characterization of the lung disease by lung biopsy may be appropriate [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         It is important to determine whether the patient is experiencing a first presentation of new RA-ILD, an exacerbation of previously unknown ILD (usually a predominantly fibrotic pattern), or one of these possibilities combined with a superimposed comorbid disease not directly due to RA. Investigations evaluating the various pulmonary manifestations of RA [
         <a href="#rid2">
          2
         </a>
         ] are designed to exclude the possibility that another lung disease or extrapulmonary process is etiologic or coexistent, such as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection (especially in an immunosuppressed host)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-induced lung disease [
         <a href="#rid55">
          55
         </a>
         ] (eg,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , anti-tumor necrosis factor-alpha [TNF-alpha]) (see
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypersensitivity pneumonitis due to an inhalational exposure (see
         <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A new or intercurrent ILD, such as acute interstitial pneumonitis or vasculitis, if symptoms are rapidly progressive
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart failure, pulmonary embolism, cancer, or recurrent gastroesophageal aspiration
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with RA, a chest radiograph is often obtained initially to assess complaints of dyspnea or abnormal findings on lung examination. However, patients with ongoing suspicion of RA-ILD due to symptoms, examination findings, or pulmonary function abnormalities require cross-sectional imaging with HRCT to assess for milder disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest radiograph
         </strong>
         – The chest radiograph may be normal in patients with early or mild RA-ILD. When abnormal, potential chest radiograph findings include bibasilar ground-glass opacities, reticular and nodular opacities, patchy opacifications, and honeycombing. Late in the course of the disease, changes suggestive of pulmonary hypertension (eg, enlargement of central pulmonary arteries, attenuation of peripheral vessels) may be detectable. (See
         <a class="medical medical_review" href="/z/d/html/6979.html" rel="external">
          "Evaluation of diffuse lung disease by conventional chest radiography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-resolution computed tomography
         </strong>
         – HRCT should be obtained in patients with symptoms, PFT findings, or chest radiograph abnormalities suggestive of diffuse parenchymal disease. Both prone and supine views are preferably obtained to avoid misinterpretation of gravity-induced opacities in dependent areas. HRCT detects abnormalities earlier than chest radiography and may reveal a range of parenchymal findings [
         <a href="#rid39">
          39,56
         </a>
         ]. In one study of 20 nonsmoking patients with RA and normal chest radiographs, five patients had basilar bronchiectasis and one had mild ILD by HRCT [
         <a href="#rid57">
          57
         </a>
         ]. In a review of 84 patients with longstanding RA, 29 percent of asymptomatic and 69 percent of symptomatic patients had abnormalities on HRCT [
         <a href="#rid58">
          58
         </a>
         ]. These findings included bronchiectasis or bronchiolectasis in the absence of fibrosis (19 percent); ground-glass attenuation (14 percent); nonseptal linear attenuation (18 percent); and honeycombing (10 percent). In general, the HRCT findings accurately predict pathologic patterns. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HRCT can distinguish a predominantly ground-glass pattern from reticular changes and honeycombing, which is helpful in differentiating among the various types of ILD. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ground-glass opacification is consistent with NSIP, acute interstitial pneumonia, and desquamative interstitial pneumonia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reticular changes, traction bronchiectasis, and honeycombing are more typical of UIP  (
         <a class="graphic graphic_diagnosticimage graphicRef75204" href="/z/d/graphic/75204.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid8">
          8,59-61
         </a>
         ]. Infrequently, however, the HRCT may suggest UIP, but NSIP will be identified by biopsy [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent areas of subpleural consolidation are more suggestive of organizing pneumonia [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Review of previously performed CT images, including abdominal CTs with views that include the lung bases, may identify a preexisting ILD. In addition, review of older images can help determine the rate of progression of ILD and whether the timing of changes in CT findings over time correlates with symptoms or medication usage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal method for using CT scans to identify the underlying histopathology and monitor for progression of RA-ILD has not been determined. One method may be to combine scoring systems used in other forms of ILD. In one combined case series, 157 patients with RA-ILD were characterized using: 1) a visual scoring system for systemic sclerosis ILD; 2) the Fleischner Society guidelines for idiopathic pulmonary fibrosis (IPF); and 3) an automated computer-based CT analysis (CALIPER) and followed for approximately three years [
         <a href="#rid62">
          62-64
         </a>
         ]. The combination of the two visual CT-based scoring systems identified a progressive fibrotic subset of the original cohort with poor prognosis similar to that of IPF (c-statistic of 0.71); the automated CT analysis further improved the predictive accuracy. Automated scoring systems are currently a research tool but have promise for the future [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">
          "Prognosis and monitoring of idiopathic pulmonary fibrosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3246822964">
         <span class="h2">
          Laboratory studies
         </span>
        </p>
        <p class="headingAnchor" id="H3062815148">
         <span class="h3">
          Routine evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with (or without) RA who present with diffuse lung disease, we generally obtain a complete cell count and differential to look for leukocytosis (infection), leukopenia (immune suppression due to medication), or eosinophilia (possible drug reaction). A serum natriuretic peptide level is useful to evaluate for heart failure or pulmonary hypertension.
        </p>
        <p>
         Most patients have already had serologic testing for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, but full assessment of other autoantibodies should be performed, including antinuclear antibodies and anti-double-stranded DNA antibodies, and also cryoglobulins to assess for coexistent rheumatic disease that may be contributory in the appropriate clinical setting, such as when purpura, Raynaud phenomenon, skin ulcers, or renal disease are present. RF may be present in high titer in patients with ILD [
         <a href="#rid20">
          20
         </a>
         ]. Anti-citrullinated peptide antibody (ACPA) positivity also correlates with the presence of RA-ILD and higher titers may be associated with more severe ILD [
         <a href="#rid20">
          20,26,66,67
         </a>
         ].
        </p>
        <p>
         While the sedimentation rate and C-reactive protein correlate with activity of RA joint disease, their role in the evaluation of lung disease is unclear.
        </p>
        <p class="headingAnchor" id="H4031666266">
         <span class="h3">
          Experimental serum markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         No serum markers have demonstrated clinical utility for the diagnosis of RA-associated ILD, although some may be promising.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Krebs von den Lungen-6 (KL-6)
         </strong>
         – Increased serum concentrations of KL-6, a glycoprotein found predominantly on type II pneumocytes and alveolar macrophages, have been reported in patients with UIP [
         <a href="#rid68">
          68
         </a>
         ]. As an example, one study assessed the potential role of serum KL-6 for the diagnosis of ILD associated with systemic inflammatory disorders in 57 patients, 22 of whom had known ILD [
         <a href="#rid69">
          69
         </a>
         ]. Patients with ILD had significantly higher KL-6 values than those without lung disease, with the sensitivity and specificity ILD estimated at 61 and 99 percent, respectively, in this selected population. Measurement of serum KL-6 remains a research tool at present but may become clinically useful in the future if the high specificity of the test is confirmed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytokines and matrix metalloproteinases
         </strong>
         – Another report noted that serum anti-interleukin-1-alpha antibody titers were significantly higher in patients with RA and ILD, in comparison to patients with RA but not ILD, and to controls. Higher titers were associated with higher serum lactate dehydrogenase concentrations and larger alveolar to arterial oxygen gradients [
         <a href="#rid70">
          70
         </a>
         ]. In addition, a matrix metalloproteinase-7 (MMP-7) and interferon-gamma-inducible protein-10 (IP-10/CXCL10) were found to be elevated in all patients with RA-ILD and a dose-response relationship was seen between the levels of these markers and radiographic severity [
         <a href="#rid71">
          71
         </a>
         ]. A different matrix metalloproteinase and C-X-C motif cytokine pair (MMP-13 and CXCL11) were associated with RA-ILD progression over five years [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoantibodies
         </strong>
         –
         <strong>
         </strong>
         In a case series (58 patients with RA-ILD; 27 with RA but no ILD), serum antibodies to citrullinated Hsp90 appeared specific (&gt;95 percent), although not sensitive, for RA-ILD [
         <a href="#rid24">
          24
         </a>
         ]. Anti-citrullinated Hsp90 antibodies were not found in 41 patients with mixed connective tissue disease or 33 patients with IPF, further suggesting specificity. The role of these autoantibodies to citrullinated-Hsp90 in identifying patients with RA-associated ILD needs validation in other groups of patients with RA. In a separate study, a stronger association was observed between the number of ACPAs and radiographic UIP than with NSIP [
         <a href="#rid26">
          26
         </a>
         ]. In a meta-analysis, serum ACPA positivity was associated with an increased odds ratio (OR) of ILD (OR 3.39, 95% CI 1.67-6.88) [
         <a href="#rid67">
          67
         </a>
         ]. If confirmed, the serum ACPA would be a very useful test to help predict RA-ILD among patients with RA.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3764396268">
         <span class="h2">
          Pulmonary function testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We obtain spirometry, lung volumes, diffusing capacity and pulse oximetry in all patients with suspected ILD in order to assess the pattern, severity, and progression of respiratory impairment.
        </p>
        <p>
         Abnormalities associated with ILD include reductions in vital capacity, lung volumes, and diffusing capacity for carbon monoxide (DLCO), oxygen desaturation during exercise, and (in late disease) resting hypoxemia. For example, in a study of 81 patients with recent-onset RA, 33 percent had a DLCO &lt;80 percent of predicted, while only 14 percent had symptoms [
         <a href="#rid5">
          5
         </a>
         ]. When assessing changes over time, clinically important differences include a decrease in forced vital capacity(FVC) of ≥10 percent predicted or a change in DLCO of ≥15 percent [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Pulmonary function testing'
         </a>
         .)
        </p>
        <p>
         Among patients with RA, restrictive abnormalities on PFTs are common even in the absence of symptoms and may reflect poor muscle strength or kyphosis due to osteoporosis rather than ILD. The association of restrictive abnormalities and evidence of abnormal gas exchange (eg, reduced DLCO, low pulse oxygen saturation) favor the diagnosis of ILD.
        </p>
        <p>
         Breathlessness and hypoxemia are usually more evident on exertion than at rest. Thus, measuring oximetry during exertion or a six-minute walk test provides more information regarding abnormal gas exchange than resting values. Arterial blood gases and cardiopulmonary exercise testing are occasionally required to corroborate abnormal pulse oxygen saturation or elucidate the etiology of dyspnea.
        </p>
        <p class="headingAnchor" id="H2044779501">
         <span class="h2">
          Invasive testing, in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary role for invasive testing is to rule out infections or malignancies or to obtain pathologic information that would alter management. Because most patients with RA-ILD are treated with anti-inflammatory therapies and/or antifibrotics based on clinical and radiographic criteria, lung biopsy is uncommon in current practice.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients presenting with interstitial abnormalities after acute onset of fever or respiratory symptoms, BAL is helpful to exclude acute eosinophilic pneumonia, alveolar hemorrhage, malignancy, or opportunistic or atypical infections [
         <a href="#rid54">
          54
         </a>
         ]. BAL is frequently abnormal in patients with RA-ILD, but the findings are nonspecific and not helpful for management. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         Abnormalities in cellular constituents and mediators found on BAL are not generally useful for diagnosis or management. The following BAL findings have been reported from research studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with clinical evidence of RA-ILD, total cells, neutrophils, and occasionally eosinophils are elevated [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of symptoms, lymphocytosis is more common [
         <a href="#rid73">
          73,74
         </a>
         ]. This finding may be associated with a better prognosis, as evidenced by the subclinical nature of the lung disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrophages isolated from BAL demonstrated increases in the production of TNF-alpha, superoxide anion, fibronectin, and collagenase activity [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         As HRCT patterns have been found to correlate reasonably closely with ILD histopathologic patterns, lung biopsy is rarely required in patients with RA-ILD [
         <a href="#rid61">
          61
         </a>
         ]. We typically consider lung biopsy on a case-by-case basis when clinical and radiographic findings are ambiguous after multidisciplinary discussion and the underlying lung pathology is likely to alter management decisions. A transbronchial biopsy obtained via flexible bronchoscopy is usually inadequate for ILD histopathologic diagnosis, so lung biopsy is typically performed by either video-assisted thoracoscopy or open thoracotomy. The decision about whether a lung biopsy should be performed should take into account the patient’s clinical condition and the potential for complications, including exacerbation of fibrotic ILD. The role of transbronchial cryobiopsy remains unclear and is described separately. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Role of lung biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16921.html" rel="external">
          "Interpretation of lung biopsy results in interstitial lung disease", section on 'Interstitial pneumonias'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H102323238">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of RA-ILD is generally based on the combination of compatible clinical features; pulmonary function testing (PFT; eg, restrictive changes and a gas transfer abnormality); high-resolution CT (HRCT) findings (eg, reticular, ground-glass, or consolidative changes); and also exclusion of other processes, such as infection, drug-induced pulmonary toxicity, and malignancy. The use of a multidisciplinary team meeting, including pulmonologists, radiologists, and rheumatologists/immunologists, is encouraged [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Determination of the underlying pattern of RA-ILD is based on a typical HRCT pattern or, less commonly, on lung biopsy findings. (See
         <a class="local">
          'Imaging'
         </a>
         above and
         <a class="local">
          'Pathologic patterns'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H113797617">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with RA, the differential diagnosis of diffuse lung disease includes drug-induced lung toxicity, opportunistic infection, heart failure, recurrent aspiration, malignancy, and other inflammatory causes of ILD. In addition, patients presenting with new respiratory symptoms with evidence of ILD may have an exacerbation of previously unknown ILD. In the latter situation, obtaining old CT images, even if performed for an abdominal problem, may provide clues to preexisting disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced lung toxicity
         </strong>
         – Drug-induced lung toxicity has been associated with most of the medications used to treat RA, including nonsteroidal anti-inflammatory drugs (NSAIDs),
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         , gold,
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         , and biologic agents (eg, tumor necrosis factor [TNF] inhibitors,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         ) [
         <a href="#rid79">
          79
         </a>
         ]. Toxicity has rarely been reported with
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         and not with
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         . An essential step in the evaluation of possible drug-induced lung toxicity is to stop any implicated medication(s) and observe for improvement over the next few days to weeks. (See
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Development of a sarcoid-like reaction in the lungs has been reported with
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , and
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         and appears to be a class effect of anti-TNF-alpha agents [
         <a href="#rid80">
          80-84
         </a>
         ]. Patients may present with dry cough, night sweats, and weight loss [
         <a href="#rid85">
          85
         </a>
         ]. Onset of disease ranges from 1 to 50 months after initiation of the anti-TNF agent [
         <a href="#rid85">
          85
         </a>
         ]. Sarcoid-like granulomas have also been reported in the skin, lymph nodes, and bone marrow in association with anti-TNF-alpha agents. In one series, the serum angiotensin-converting enzyme level was elevated in 48 percent of patients [
         <a href="#rid86">
          86
         </a>
         ]. Cessation of the anti-TNF-alpha agent generally leads to resolution of the granulomas over several months [
         <a href="#rid87">
          87
         </a>
         ]. Recurrences have been reported when the same anti-TNF-alpha agent is resumed but appears less common when an alternate agent is used [
         <a href="#rid85">
          85,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opportunistic infection
         </strong>
         – Opportunistic infections are well-known complications of immunosuppressive therapies used to treat RA. The diagnosis of opportunistic infections typically requires special stains and culture of induced sputum and/or bronchoalveolar lavage (BAL) specimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          Pneumocystis
         </em>
         (
         <em>
          jirovecii
         </em>
         ) pneumonia (PCP) is associated with all of the immunosuppressive agents, particularly when the patient is receiving a glucocorticoid dose equivalent to ≥20 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         daily for one month or longer in addition to a second immunosuppressive agent, or taking an anti-TNF-alpha agent in combination with other intensive immunosuppression. PCP should be in the differential of new, recent-onset dyspnea, fever, and diffuse of patchy radiographic disease. (See
         <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Anti-TNF-alpha agents also increase the risk for new and reactivated latent fungal infections, such as histoplasmosis, coccidioidomycosis, cryptococcosis, and other invasive fungal infections. (See
         <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Mycobacterial disease (both tuberculous and nontuberculous) is a well-described complication of anti-TNF-alpha agents. (See
         <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">
          "Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypersensitivity pneumonitis
         </strong>
         – The clinical, imaging, and histopathologic characteristics of chronic hypersensitivity pneumonitis are similar to those of the usual interstitial pneumonia (UIP) pattern of RA-ILD. The radiographic findings typical of subacute hypersensitivity pneumonitis (eg, diffuse micronodules, ground-glass attenuation) are also seen in some patients with RA and organizing pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causes
         </strong>
         – Heart failure is generally excluded based on physical examination, natriuretic peptide measurement, and echocardiogram.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recurrent aspiration typically affects the lower lobes and may demonstrate tree-in-bud abnormalities or an airway-centric distribution of inflammation; swallowing difficulties provide a clue to the diagnosis, although they are not always present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The additional differential diagnosis of diffuse lung disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for RA-ILD has not been determined. Asymptomatic and mildly affected patients may be monitored clinically and with serial pulmonary function testing (PFT). For patients with more advanced or progressive disease, treatment with immunosuppressive agents may target both the pulmonary pathology and the underlying autoimmune process. For lung disease alone, our contributors prefer steroid-sparing agents (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) except for those presenting with likely organizing pneumonia, in which case corticosteroids are preferred. However, patients may be managed with a combination of agents (eg, with corticosteroids to control joint disease as well as steroid-sparing agents for their lung disease).
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         has been shown to slow progression in those with progressive fibrosing disease [
         <a href="#rid88">
          88
         </a>
         ] and may be used in addition to other therapy.
        </p>
        <p class="headingAnchor" id="H3775349680">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive measures, including evaluation for supplemental oxygen, patient education, pulmonary rehabilitation, smoking cessation, vaccination for the prevention of pulmonary infections, and palliation of pulmonary symptoms, are similar in all patients with interstitial lung disease. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Supportive care'
         </a>
         .)
        </p>
        <p>
         Patients with advanced disease are appropriate for referral for palliative care and/or lung transplantation. (See
         <a class="local">
          'Lung transplantation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">
          "Palliative care for adults with nonmalignant chronic lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H961313773">
         <span class="h2">
          Deciding whom to treat
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to treat RA-ILD needs to weigh prognosis, likelihood of response to therapy, and potential benefits of early therapy (ie, before fibrosis is established) against the potentially significant adverse effects of treatment (eg, risk of infection). Abnormalities in any single PFT are common in patients with RA. Thus, the diagnosis of clinically significant disease that warrants close monitoring or treatment is based upon the severity of impairment, rate of progression, and pattern of abnormalities identified by the investigations described above, rather than results of a single test.
        </p>
        <p>
         As a way to guide treatment and monitoring strategies, a newer approach used in guidelines for idiopathic interstitial pneumonias has been to categorize the disease behavior as self-limited, reversible, stable, progressive, or irreversible, with or without the potential for long-term stabilization with therapy  (
         <a class="graphic graphic_table graphicRef102358" href="/z/d/graphic/102358.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid2">
          2,41,89
         </a>
         ]. At present, predictors of poor prognosis (eg, low diffusing capacity or extensive fibrosis on the high-resolution CT [HRCT]), combined with observed rate of progression offer the best guide to treatment decisions in the face of infrequent pathologic confirmation and heterogeneous outcomes.
        </p>
        <p class="headingAnchor" id="H110204594">
         <span class="h2">
          Patients with mild ILD or stable fibrotic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For asymptomatic patients and those with mild RA-ILD (eg, mild dyspnea or cough, vital capacity, lung volumes, and diffusing capacity ≥70 percent predicted), we suggest clinical follow-up and PFT surveillance, rather than anti-inflammatory or antifibrotic therapy. Chest imaging (typically HRCT) should be obtained in the setting of new symptoms or PFT decline.
        </p>
        <p>
         Similarly, for patients with a usual interstitial pneumonia (UIP) pattern and stable disease by symptoms, PFTs, and HRCT, we suggest monitoring without specific therapy (other than treatment of their articular disease) rather than other treatments. However, close clinical and PFT monitoring are appropriate to allow for early treatment of disease progression. (See
         <a class="local">
          'Antifibrotic therapy, for progressive fibrosis'
         </a>
         below.)
        </p>
        <p>
         Typically, these latter patients are older, and their RA-ILD is less likely to respond to glucocorticoids or immunosuppressive therapies. Therapy of their joint disease continues as indicated, although any drugs that may have contributed to lung toxicity are discontinued. (See
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Initial therapy for more severe or progressive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with more severe or progressive interstitial lung disease, we suggest initiation of anti-inflammatory therapy, typically with steroid-sparing agents (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ), rather than upfront antifibrotic therapy or expectant management. Features that suggest treatment of RA-ILD with anti-inflammatory therapies is likely to be beneficial include younger age and worsening of symptoms, PFTs, or HRCT over the preceding three to six months (ie, reversible or progressive disease  (
         <a class="graphic graphic_table graphicRef102358" href="/z/d/graphic/102358.html" rel="external">
          table 4
         </a>
         )). The decision to commence therapy is also influenced by the presence of comorbid diseases that might increase the risk of adverse effects from immunosuppression or toxicities of individual agents. There are only sparse data to guide anti-inflammatory treatment decisions; randomized controlled studies are needed to determine the patient subgroups most likely to benefit from a given regimen.
        </p>
        <p>
         In one observational and retrospective study of 212 patients with RA-ILD treated with immunosuppressant agents (
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ), initiation of immunosuppression correlated with stabilization in lung function trajectory [
         <a href="#rid90">
          90
         </a>
         ]. Comparing lung function trends before and after immunosuppressant initiation for all three agents, forced vital capacity (FVC) percent predicted improved by 3.9 percent (95% CI 2.0-5.8) and diffusing capacity for carbon monoxide (DLCO) by 4.5 percent (95% CI 2.1-6.9) over 12 months compared with their trajectory prior to treatment. There were no significant differences in outcomes between the different immunosuppressive agents. The drop-out rate due to side effects was slightly higher with azathioprine than mycophenolate or rituximab.
        </p>
        <p>
         Similarities between RA-ILD with a UIP pattern and idiopathic pulmonary fibrosis (IPF) have led to concern about potential harm from glucocorticoids and other anti-inflammatory therapies in these patients based on data from IPF [
         <a href="#rid91">
          91
         </a>
         ]. However, evidence from observational studies suggests a trial of immunosuppression in suitable patients is warranted, even for those with a UIP pattern [
         <a href="#rid90">
          90,92
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the observational trial of immunosuppressant therapy described above [
         <a href="#rid90">
          90
         </a>
         ], 38 percent of patients had a UIP pattern on CT, but the presence of possible or probable UIP did not impact positive treatment response significantly at 12 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in a retrospective study of 59 patients with RA-associated UIP (RA-UIP) receiving immunosuppressive therapy for ILD progression or severe disease, 50 percent of those treated improved or remained stable over a median 33-month follow-up despite the expectation that most would progress [
         <a href="#rid92">
          92
         </a>
         ]. Furthermore, the treated patients had similar survival compared with untreated patients despite worse initial lung function and disease trajectory.
        </p>
        <p>
        </p>
        <p>
         Our contributors typically avoid glucocorticoids and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         in patients with RA-UIP in the absence of prospective data verifying benefit and evidence of harm in IPF patients with UIP [
         <a href="#rid91">
          91
         </a>
         ]. In patients with RA-ILD and UIP treated with immunosuppressants, it is appropriate to monitor closely for progressive fibrosing disease, at which point we suggest treatment with antifibrotic therapy. (See
         <a class="local">
          'Antifibrotic therapy, for progressive fibrosis'
         </a>
         below.)
        </p>
        <p>
         In contrast, patients with RA-ILD accompanied by radiographic or pathologic evidence of organizing pneumonia are considered likely to respond to glucocorticoid therapy based on experience with cryptogenic organizing pneumonia and on clinical reports [
         <a href="#rid93">
          93
         </a>
         ]. We treat these patients like those with cryptogenic disease. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         For other patient groups, our contributors also typically avoid use of glucocorticoids for ILD alone (as opposed to extrapulmonary manifestations) in the absence of rapid deterioration (ie, fulminant disease), or suspicion for an acute exacerbation of fibrotic ILD. As glucocorticoids act more quickly than most other immunosuppressive regimens, they are used routinely in these settings. (See
         <a class="local">
          'Treatment of fulminant disease'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H479042434">
         <span class="h3">
          Dosing and administration of individual agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data regarding the efficacy of individual agents for RA-ILD are highly limited, so recommendations are based primarily on case series and clinical experience. British and Spanish guidelines favor
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as they appear to have a lower likelihood of worsening preexisting ILD or development of new-onset ILD compared with other biologic disease-modifying anti-rheumatic drugs (DMARDs) [
         <a href="#rid94">
          94,95
         </a>
         ]. Decisions are made on a case-by-case basis, considering patient experience with other agents, the treatment requirements of extrapulmonary disease, and adverse effects of individual agents in the context of patient comorbidities. Dosing and administration of DMARDs are generally similar to their use in other settings, except where otherwise noted.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         – When used for ILD, mycophenolate mofetil is initiated at 500 mg given twice a day and is increased as tolerated to a target dose of 2 to 3 g/day. Clinical experience suggests lower daily doses are often not effective for this indication. In addition, mycophenolate is not effective in the treatment of articular manifestations of RA [
         <a href="#rid96">
          96
         </a>
         ], so may need to be added to other DMARDs. The administration of mycophenolate is described separately. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence in favor of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         for RA-ILD comes from a series of 125 patients with connective tissue disease-associated ILD (CTD-ILD), including 18 with RA [
         <a href="#rid97">
          97
         </a>
         ]. Mycophenolate mofetil was associated with modest improvements in FVC and diffusing capacity and reductions in the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose (mean decrease among RA patients 20 mg). The discontinuation rate for adverse effects (gastrointestinal intolerance, hepatic transaminase elevation, cytopenia, and nonspecific symptoms) was under 10 percent. One study using registry data did not suggest an increased risk for malignancy with mycophenolate treatment for CTD-ILD [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         – Rituximab is a B lymphocyte-depleting biologic agent effective for RA-ILD and also used in patients whose RA is inadequately controlled by other biologic DMARDs. After preparative immunizations (eg, pneumococcal, seasonal influenza, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), serologic testing (eg, hepatitis B, hepatitis C, human immunodeficiency virus [HIV]), checking immunoglobulin levels (immunoglobulin G [IgG] and immunoglobulin M [IgM]), and screening for tuberculosis, rituximab is administered as two intravenous infusions of 1000 mg, 14 days apart. In general, if low-dose glucocorticoids (eg, 10 mg daily) or a DMARD have been used for extrapulmonary disease, they are continued. Details of the treatment protocols are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence in favor of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         comes from a retrospective cohort study of 44 patients with moderate to severe RA-ILD, in which addition of rituximab was associated with stabilization or improvement in lung function in 30 patients (68 percent) [
         <a href="#rid99">
          99
         </a>
         ]. However, 14 patients (32 percent) experienced progressive lung disease and, of these, seven died. In two smaller case series, rituximab was associated with stabilization of lung disease or modest improvement in a portion of the patients [
         <a href="#rid100">
          100,101
         </a>
         ], although adverse effects included infusion reactions, heart failure, and possible pneumonia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          Abatacept
         </a>
         – Abatacept is a fusion protein (CTLA-Ig) that inhibits activation of T lymphocytes by blocking interaction between CD28 and CD80. Screening for infection and preparation with vaccination, as for many of these agents, should occur before treatment is commenced. Abatacept is administered by intravenous infusion every four weeks or subcutaneous injection that can be self-administered weekly. In general, patients should remain on either low-dose glucocorticoids (eg, 10 mg) or a DMARD if these have been used for extrapulmonary disease. Additional details of dosing and administration are described separately. (See
         <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">
          "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Abatacept'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Retrospective data suggest a beneficial effect of
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         in RA-ILD [
         <a href="#rid96">
          96
         </a>
         ]. A multicenter, open-label study in 63 patients with RA-ILD revealed that abatacept was associated with stabilization in two-thirds and improvement in one-fourth of patients; 11 patients (17 percent) discontinued therapy due to adverse effects [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          Abatacept
         </a>
         was also associated with stability or improvement in lung function and HRCT in the majority of 44 patients with RA-ILD followed for six months [
         <a href="#rid103">
          103
         </a>
         ]. In a separate series, abatacept appeared protective against the emergence of ILD in a small number of patients with RA [
         <a href="#rid104">
          104
         </a>
         ]. However, concomitant use of abatacept and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         in patients with RA was associated with an increased risk of ILD in one case series [
         <a href="#rid105">
          105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">
          "Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Methotrexate plus abatacept'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">
          "Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Abatacept'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic glucocorticoid therapy
         </strong>
         – If a trial of corticosteroids is used as part of initial therapy (generally in combination with another immunosuppressant), it is typically given at a low dose, such as 0.25 mg/kg ideal body weight per day (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ), as a single morning dose [
         <a href="#rid54">
          54
         </a>
         ]. If a response is going to occur, it is usually seen within one to three months. The
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose should be slowly reduced to a maintenance dose of 10 mg/day once a response occurs, using symptomatic response and PFTs to monitor disease activity. Most patients are transitioned to a separate DMARD (or begun on one upfront) as a steroid-sparing agent to facilitate tapering and minimization of prednisone. Use of systemic glucocorticoids for organizing pneumonia or fulminant disease are covered separately and below. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Initial approach'
         </a>
         and
         <a class="local">
          'Treatment of fulminant disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agents that are less commonly used
         </strong>
         – Accumulating evidence suggests that
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         does not typically cause worsening of lung disease and is unlikely to be a culprit agent for development of RA-ILD [
         <a href="#rid106">
          106
         </a>
         ]. This makes it acceptable as a maintenance therapy for joint disease in patients with stable RA-ILD, but our authors do not use it for treatment of worsening lung disease. Methotrexate-related acute (hypersensitivity) pneumonitis is exceedingly rare, but methotrexate discontinuation is appropriate in those with appropriate symptoms and radiographic findings without other likely potential antigens. (See
         <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">
          "Use of methotrexate in the treatment of rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis", section on 'Methotrexate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tumor necrosis factor-alpha (TNF-alpha) inhibitors are less often used in patients with RA-ILD because of multiple, although infrequent, case reports of lung toxicity with these agents [
         <a href="#rid94">
          94-96
         </a>
         ]. Conflicting data have been presented for
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         in RA-ILD [
         <a href="#rid96">
          96,107
         </a>
         ].
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         was used successfully in combination with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         in a small case series, but it is almost never used as a single agent for RA-ILD [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3167804492">
         <span class="h2">
          Treatment of fulminant disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the minority of patients who develop rapidly progressive acute ILD or organizing pneumonia as a complication of RA, after excluding infection and drug-induced lung toxicity, we follow treatment regimens for the particular type of ILD (eg, acute interstitial pneumonitis, organizing pneumonia). As these patients typically have impending or actual respiratory failure, we suggest high-dose systemic glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         500 to 1000 mg per day given intravenously as a pulse or in divided doses for three to five days) [
         <a href="#rid96">
          96,109
         </a>
         ]. An immunosuppressive agent may be added at the same time, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid110">
          110
         </a>
         ],
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , although evidence in favor of this practice is limited. Concomitant empiric antibiotics are prudent pending results of microbiologic studies. (See
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Patients with rapidly progressive disease or respiratory failure'
         </a>
         .)
        </p>
        <p>
         Data are limited regarding the role of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in fulminant RA-ILD [
         <a href="#rid110">
          110
         </a>
         ]. A systematic review of cyclophosphamide in CTD-ILD found that cyclophosphamide has, at best, a modest benefit in preserving lung function [
         <a href="#rid111">
          111
         </a>
         ]. Cyclophosphamide can be administered as intravenous infusions monthly or taken orally every day. Given the toxicity of cyclophosphamide, use of this drug is generally reserved for more severe or refractory disease, and the duration of treatment is limited to six months. The administration of cyclophosphamide is described separately. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         Prognosis in fulminant disease is poor, and depending on the patient's age, other comorbidities, and patient wishes, a symptom-based palliative approach may be appropriate. (See
         <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">
          "Palliative care for adults with nonmalignant chronic lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H459073961">
         <span class="h2">
          Disease progression despite initial treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with RA-ILD, disease progression is frequent despite optimal medical management. The symptoms of disease progression, such as worsening cough, dyspnea, or hypoxemia, commonly overlap with other conditions such as respiratory infection, acute decompensated heart failure, pulmonary hypertension, pulmonary embolism, or pneumothorax. Additionally, worsening pulmonary symptoms can be triggered by acute exacerbation of fibrotic ILD, drug toxicity, malignancy, anemia, coronary artery disease, and deconditioning, among others.
        </p>
        <p>
         For patients with worsening pulmonary symptoms, initial evaluation to the cause of worsening often includes PFTs and imaging, such as a chest radiograph or CT, tailored based on the presenting symptoms.
        </p>
        <p>
         For patients who have suspected worsening of ILD after work-up for alternative causes, therapeutic options differ depending on whether the progression is characterized by worsening fibrosis or other processes more likely to be amenable to anti-inflammatory therapies. In either case, referral for lung transplantation evaluation is reasonable for patients who are otherwise appropriate candidates.
        </p>
        <p class="headingAnchor" id="H2201586358">
         <span class="h3">
          Adjunctive immunosuppression, for worsening nonfibrotic ILD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients experiencing clinical worsening of their RA-ILD without evidence of worsening or exacerbating fibrotic ILD, our typical approach is to add or change disease-modifying antirheumatic therapies. For patients on
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , this typically involves adding
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         ; for those on one of these therapies, we would usually add mycophenolate or switch from one to the other. Depending on the pace of clinical worsening, glucocorticoids may also be used as a bridge to therapeutic control with these other agents. Dosing and administration are as noted above. (See
         <a class="local">
          'Dosing and administration of individual agents'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3141905776">
         <span class="h3">
          Antifibrotic therapy, for progressive fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with RA, HRCT features of fibrosing ILD, and clinical evidence of declining lung function despite immunosuppressive therapies, we suggest treatment with the antifibrotic
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         to slow disease progression. Based on clinical trials and accumulating evidence of clinical efficacy of nintedanib across studies, patients most likely to benefit include those with reticular abnormalities with traction bronchiectasis (with or without honeycombing) on HRCT and a fall in FVC of 10 percent predicted despite initial treatment. Nintedanib has also been shown to slow decline in lung function in other predominantly fibrotic lung diseases, including IPF and systemic sclerosis-associated ILD. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Nintedanib'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         was evaluated in a trial (INBUILD) that included 663 patients with various progressive fibrosing ILDs that had worsened despite standard of care and who had at least 10 percent of the lung affected as seen on HRCT [
         <a href="#rid88">
          88
         </a>
         ]. Thirteen percent of patients included had RA-ILD. Evidence of disease progression required for enrollment included any of the three following criteria: relative decline in the FVC of at least 10 percent of the predicted value; a relative decline in the FVC of 5 to 10 percent of predicted and worsening of respiratory symptoms or increased extent of fibrosis on HRCT; or both worsening of respiratory symptoms and an increased extent of fibrosis. After 52 weeks:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the overall population,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         slowed the overall adjusted rate of decline in FVC with a between-group difference of 107.0 mL/year (95% CI 65.4-148.5), which is comparable to the benefit seen in IPF. The results of this trial lend support to the concept that fibrotic lung disease reflects a final common pathway that is initiated in a spectrum of ILDs and that this phase of disease may respond to antifibrotic agents that are not disease specific. Additional details about the trial are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Nintedanib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4311.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Treatment, prognosis, and prevention", section on 'Antifibrotic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a posthoc subgroup analysis of 89 patients with RA-ILD, the rate of FVC decline was -79 mL/year with
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         compared with -197 mL/year with placebo (absolute difference 118 mL/year, 95% CI 5.2-231 mL) [
         <a href="#rid112">
          112
         </a>
         ]. Among a larger subgroup of 170 patients with progressive fibrosing ILD associated with autoimmune diseases, there was a trend towards decreased ILD exacerbation or death that did not reach statistical significance (10 versus 18 events).
        </p>
        <p>
        </p>
        <p>
         The dosing of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         for patients with RA and progressive fibrotic lung disease follows that for IPF and is described separately, as are potential adverse effects. Cost, side effects, and availability may limit use. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'
         </a>
         .)
        </p>
        <p>
         For patients who do not tolerate or otherwise cannot take
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         , some of our contributors offer a trial of the alternative antifibrotic
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         (off-label), although data are limited and lack of regulatory approval may impact affordability and availability. (See
         <a class="local">
          'Future directions'
         </a>
         below.)
        </p>
        <p>
         Although patients with progressive lung fibrosis frequently require systemic glucocorticoids, oral immunosuppressants, or biological agents for extrapulmonary disease, there are limited data regarding the coadministration of these agents and antifibrotics. In our practice, we typically add
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         onto the patient's current disease-controlling therapies. The INBUILD trial excluded patients on
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , or oral glucocorticoids &gt;20 mg/day. Ongoing trials are evaluating the safety and efficacy of combinations of agents.
        </p>
        <p class="headingAnchor" id="H281937217">
         <span class="h3">
          Lung transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progressive RA-ILD despite anti-inflammatory therapy carries a poor prognosis, regardless of underlying pathology. Patients with ILD due to causes other than IPF make up 40 percent of the population transplanted for ILD, and criteria have been established for placing these patients on the transplant list [
         <a href="#rid113">
          113
         </a>
         ]. Among 10 patients with RA-ILD who underwent lung transplantation, survival at one year was comparable to lung transplantation recipients with IPF, 67 and 69 percent, respectively [
         <a href="#rid114">
          114
         </a>
         ]. A modest improvement in quality of life with respect to respiratory symptoms was also noted. Side effects of the therapy for RA (eg, osteoporosis) may be a contraindication; other extrapulmonary disease manifestations may also complicate transplantation. (See
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          MONITORING PATIENTS ON RA-ILD THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are being treated with glucocorticoids, disease-modifying anti-rheumatic drugs (DMARDs), or antifibrotic agents, monitoring for an objective response to treatment is generally performed at three-month intervals with clinical assessment and pulmonary function testing (PFT), along with judicious use of high-resolution CT (HRCT) chest imaging based on clinical course.
        </p>
        <p>
         Monitoring for adverse effects of therapies for RA-ILD is essential. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring for nonpulmonary organ toxicity
         </strong>
         – Hematologic monitoring is needed with most immunosuppressive agents (eg, monthly initially and then every three months). In addition to hematologic monitoring, liver function tests are obtained monthly at first and then every three months for patients on
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , antifibrotic therapies, and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . Additional details about the administration and monitoring of these agents are provided in the table and separately  (
         <a class="graphic graphic_table graphicRef78846" href="/z/d/graphic/78846.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Mycophenolate dose and administration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Medical therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced pulmonary toxicity
         </strong>
         – Almost all of the DMARDs and biologic therapies have been associated with lung toxicity  (
         <a class="graphic graphic_table graphicRef65141" href="/z/d/graphic/65141.html" rel="external">
          table 2
         </a>
         ), so clinicians should keep this possibility in mind should unexpected worsening of ILD occur during therapy. (See
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An important clinical question is whether drugs known to cause lung toxicity should be avoided in patients with underlying lung abnormalities due to concern about potential exacerbation. A systematic review has shown the overall risk of a drug reaction is low (1 percent), although if a reaction occurs, it often has a high mortality [
         <a href="#rid79">
          79
         </a>
         ]. Potentially life-benefiting antirheumatic medications should not necessarily be withheld for what appears to be an uncommon side effect, but such patients do require ongoing monitoring for worsening respiratory symptoms or function. (See
         <a class="medical medical_review" href="/z/d/html/4378.html" rel="external">
          "Drug-induced lung disease in rheumatoid arthritis", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – A variety of serious infections have been described with use of these immunosuppressive therapies. Prophylaxis against
         <em>
          Pneumocystis (jirovecii)
         </em>
         pneumonia (PCP)may be warranted for some of the above treatment regimens. While the low doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         typically used in RA do not warrant prophylaxis, the combination of a glucocorticoid dose equivalent to ≥20 mg of prednisone daily for one month or longer and a second immunosuppressive agent, or the combination of an anti-tumor necrosis factor-alpha (TNF-alpha) agent with other intensive immunosuppression, may warrant prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections", section on 'Pneumocystis pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vaccination with the influenza vaccine should be provided annually to all patents with RA. Vaccination to prevent coronavirus disease 2019 (COVID-19) is recommended for all individuals 12 years and older. Administration of the polysaccharide pneumococcal vaccine is recommended in all adults with chronic lung disease. In addition, a second dose of the polysaccharide vaccine five years after the first is suggested in patients receiving immunosuppressive therapies. The pneumococcal conjugate vaccine is also suggested in such patients  (
         <a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignancy
         </strong>
         – Patients on long-term therapy with cytotoxic medications are at risk of developing malignancy, particularly skin, cervical, and (with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) bladder cancer. Thus, patients should be educated about avoidance of the sun and use of sunblock, and women should receive regular mammograms and cervical Papanicolaou smears.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2851518333">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with RA, the presence of RA-ILD is associated with greater mortality compared with the absence of ILD (five-year mortality 36 percent and 18 percent, respectively) [
         <a href="#rid115">
          115
         </a>
         ]. Among patients with RA-ILD, the following factors affect prognosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Demographics
         </strong>
         – The prognosis of RA-ILD depends on sex and age. Females contribute to the greatest number of deaths given the increased prevalence of RA in females, but males with RA are at increased risk of developing RA-ILD [
         <a href="#rid14">
          14,116
         </a>
         ]. Older age has been significantly associated with increased mortality in several cohorts of patients with RA-ILD [
         <a href="#rid14">
          14,92,117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease subtype
         </strong>
         – Overall, a radiographic or histologic pattern consistent with usual interstitial pneumonia (UIP) portends a greater likelihood of ILD progression and mortality [
         <a href="#rid118">
          118-120
         </a>
         ]. For example, the effect of presumed histopathologic subtype was assessed in a retrospective review of 144 patients with RA-ILD using high-resolution CT (HRCT) and (in a smaller number of patients) pathology [
         <a href="#rid118">
          118
         </a>
         ]. The poorest survival at five years was in those with diffuse alveolar damage (20 percent) and UIP (37 percent), while a better prognosis was found for organizing pneumonia (60 percent), bronchiectasis (87 percent), bronchiolitis (89 percent), and nonspecific interstitial pneumonia (NSIP; 94 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, for some patients with RA-ILD and a UIP pattern, the pulmonary abnormalities do not progress and may remain subclinical. In a retrospective review of 84 patients with RA-associated UIP (RA-UIP) who were monitored for 33 months, respiratory abnormalities remained stable in approximately 50 percent (for a median of 45 months), progressed in 30 percent, and deteriorated rapidly in 17 percent [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory impairment
         </strong>
         – Baseline pulmonary function tests (PFTs) and their course over time are correlated with survival. For example, in a cohort of 158 patients with RA-ILD, a lower forced vital capacity (FVC) or a 10 percent decline in FVC was independently associated with an increased risk of death regardless of baseline CT pattern [
         <a href="#rid121">
          121
         </a>
         ]. Similarly, both decreased baseline diffusing capacity for carbon monoxide (DLCO) and a 10 to 15 percent decline in DLCO showed associations with progression of disease and mortality [
         <a href="#rid119">
          119,121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute exacerbations
         </strong>
         – Acute episodes of pulmonary decompensation are a common feature of several interstitial lung diseases and are associated with a poor prognosis, including in patients with RA-ILD [
         <a href="#rid122">
          122-124
         </a>
         ]. In one study of 310 patients with RA-ILD followed for a median of 48 months, 20 percent of patients experienced an acute exacerbation within three years [
         <a href="#rid123">
          123
         </a>
         ]. Even after accounting for age, sex, smoking status, lung function, exercise capacity, and CT scan pattern, acute exacerbations were associated with decreased survival. Thirty-day and 90-day mortality after an acute exacerbation were 13 and 30 percent, respectively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2263331516">
         <span class="h1">
          FUTURE DIRECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newer therapies for RA (eg,
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , janus kinase [JAK] inhibitors) and the antifibrotic agent
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         , which is used in idiopathic pulmonary fibrosis (IPF), may also have a role in treating RA-ILD [
         <a href="#rid1">
          1,125-130
         </a>
         ]. Research examining their effects is awaited with interest.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small retrospective study of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         in 28 patients with RA-ILD followed for a mean duration of 30 months showed stabilization, improvement, or decline in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) in 56 percent, 20 percent, and 6 percent of participants, respectively [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one case series of 43 patients with RA-ILD treated with JAK inhibitors, 89 percent of patients demonstrated stability or improvement over a median follow-up of 19 months [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antifibrotic agent
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         has shown benefit in progressive fibrotic ILD as described above (see
         <a class="local">
          'Antifibrotic therapy, for progressive fibrosis'
         </a>
         above).
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          Pirfenidone
         </a>
         , an alternative antifibrotic, slows disease progression in IPF and is being assessed in other progressive fibrotic ILDs. In an underpowered trial ended early due to the COVID pandemic, patients with RA and fibrotic ILD of any type were randomly assigned to pirfenidone (2403 mg per day) or placebo [
         <a href="#rid129">
          129
         </a>
         ]. Use of pirfenidone did not significantly change the proportion of patients with a ≥10 percent decline in FVC or death (7 [11 percent] of 63 patients in the pirfenidone group versus 9 [15 percent] of 60 patients in the placebo group). However, patients receiving pirfenidone did demonstrate a slower rate of annual FVC decline (-66 mL versus -146 mL). Additional study of pirfenidone treatment in fibrotic RA-ILD is warranted based on these results. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Pirfenidone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2660950396">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">
          "Society guideline links: Rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and risk factors
         </strong>
         – The prevalence of interstitial lung disease (ILD) in rheumatoid arthritis (RA) is somewhere between 10 and 50 percent. Risk factors for RA-associated ILD (RA-ILD) include more severe RA, high C-reactive protein, male sex, older age, obesity, cigarette smoking, exposure to fine particulate matter, anti-cyclic citrullinated peptide (anti-CCP) antibodies, and the presence of the
         <em>
          MUC5B
         </em>
         promoter variant. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Risk factors and genetic predisposition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histopathologic patterns in RA-ILD
         </strong>
         – The most common histopathologic patterns among patients with RA-ILD are those of usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). Other pathologic patterns include organizing pneumonitis, lymphoid interstitial pneumonitis, and diffuse alveolar damage  (
         <a class="graphic graphic_table graphicRef68251" href="/z/d/graphic/68251.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Pathologic patterns'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Symptoms of RA-ILD typically include insidious-onset dyspnea and a nonproductive cough. Fever, chest pain, and acute symptoms are less common. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – High-resolution computed tomography (HRCT) is essential to determine the radiographic features and extent of disease. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary function tests
         </strong>
         – Pulmonary function tests (PFTs) should be obtained in all patients with suspected ILD to assess the pattern, severity, and progression of respiratory impairment. Typical findings include a restrictive pattern with abnormal gas exchange, often accompanied by exertional hypoxemia. (See
         <a class="local">
          'Pulmonary function testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Drug-induced lung disease, infection, heart failure, recurrent gastroesophageal aspiration, and malignancy may either mimic ILD or lead to apparent deterioration in stable ILD. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of RA-ILD is generally based on the combination of clinical presentation, PFTs, HRCT, and, in selected cases, lung biopsy. Lung biopsy is reserved for patients with atypical findings (eg, rapid progression, fever, predominance of ground-glass opacities over reticular) after bronchoscopic sampling has ruled out infection. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to treatment
         </strong>
         – Clinically significant disease that warrants treatment is determined based upon the severity of impairment, rate of progression, and radiographic or histologic patterns  (
         <a class="graphic graphic_table graphicRef102358" href="/z/d/graphic/102358.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Deciding whom to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild ILD or stable fibrotic disease
         </strong>
         – For asymptomatic patients and those with mild RA-ILD (eg, mild dyspnea or cough with vital capacity, lung volumes, and diffusing capacity ≥70 percent predicted), we suggest clinical follow-up and PFT surveillance, rather than anti-inflammatory or antifibrotic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Similarly, for patients with a UIP pattern and stable disease by symptoms, PFTs, and HRCT, we suggest monitoring clinically and with serial PFTs rather than specific treatments for ILD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial therapy for more severe or progressive disease
         </strong>
         – For most patients with more severe or progressive interstitial lung disease, we suggest initiation of anti-inflammatory therapy, typically with steroid-sparing agents (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ), rather than upfront antifibrotic therapy or expectant management (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). There are only sparse data to guide anti-inflammatory treatment decisions. (See
         <a class="local">
          'Initial therapy for more severe or progressive disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with RA-ILD accompanied by radiographic or pathologic evidence of organizing pneumonia, we initiate treatment with glucocorticoids as in cryptogenic organizing pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial therapy for fulminant disease
         </strong>
         – For patients who present with fulminant ILD, after excluding infection and drug-induced lung toxicity, we suggest initial high-dose systemic glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Adjunctive agents (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) may be used in addition to glucocorticoids on a case-by-case basis. (See
         <a class="local">
          'Treatment of fulminant disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Worsening nonfibrotic ILD despite initial therapy
         </strong>
         – For patients on initial therapy experiencing clinical worsening of their RA-ILD without evidence of progressive or exacerbating pulmonary fibrosis, our typical approach is to add or change disease-modifying antirheumatic therapies. (See
         <a class="local">
          'Adjunctive immunosuppression, for worsening nonfibrotic ILD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Progressive fibrosing ILD despite initial therapy
         </strong>
         – For patients with predominant fibrotic changes on HRCT and clinical progression of disease (eg, decline in forced vital capacity [FVC] by ≥10 percent predicted) despite initial immunosuppressant treatment, we suggest the addition of the antifibrotic
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         to maintenance agents for extrapulmonary RA rather than either therapy alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Cost, side effects, and availability may limit the use of nintedanib. (See
         <a class="local">
          'Antifibrotic therapy, for progressive fibrosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring and prognosis
         </strong>
         – Monitoring disease activity includes clinical assessment, HRCT imaging, PFTs, and surveillance for adverse effects of immunosuppressant therapies. Older age, a UIP pattern on histology or chest imaging, decreased pulmonary function, and acute exacerbations of ILD are significant risk factors for disease progression and mortality. (See
         <a class="local">
          'Monitoring patients on RA-ILD therapies'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013; 143:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med 2014; 35:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994; 21:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilligan DM, O'Connor CM, Ward K, et al. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax 1990; 45:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natalini JG, Baker JF, Singh N, et al. Autoantibody Seropositivity and Risk for Interstitial Lung Disease in a Prospective Male-Predominant Rheumatoid Arthritis Cohort of U.S. Veterans. Ann Am Thorac Soc 2021; 18:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. J Rheumatol 2019; 46:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duarte AC, Porter JC, Leandro MJ. The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology (Oxford) 2019; 58:2031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samhouri BF, Vassallo R, Achenbach SJ, et al. Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort. Arthritis Care Res (Hoboken) 2022; 74:2042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013; 25:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007; 36:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 2014; 53:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shidara K, Hoshi D, Inoue E, et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 2010; 20:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012; 106:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao N, Al-Aly Z, Zheng B, et al. Fine particulate matter components and interstitial lung disease in rheumatoid arthritis. Eur Respir J 2022; 60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronzer VL, Huang W, Dellaripa PF, et al. Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. J Rheumatol 2021; 48:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 2013; 65:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deane KD, Nicolls MR. Developing better biomarkers for connective tissue disease-associated interstitial lung disease: citrullinated hsp90 autoantibodies in rheumatoid arthritis. Arthritis Rheum 2013; 65:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014; 73:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willis VC, Demoruelle MK, Derber LA, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 2013; 65:2545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikuls TR, Payne JB, Deane KD, Thiele GM. Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: The spark that lights the fire in rheumatoid arthritis? J Allergy Clin Immunol 2016; 137:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juge PA, Lee JS, Ebstein E, et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med 2018; 379:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomäki A, FinnGen Rheumatology Clinical Expert Group, Palotie A, et al. Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers. Ann Rheum Dis 2021; 80:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott G, Gill R, Gagne S, et al. Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset. Rheumatology (Oxford) 2022; 61:4915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juge PA, Solomon JJ, van Moorsel CHM, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum 2021; 51:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi S, Matsubara T, Fukuda K, et al. A genome-wide association study identifying single nucleotide polymorphisms in the PPFIBP2 gene was predictive for interstitial lung disease in rheumatoid arthritis patients. Rheumatol Adv Pract 2022; 6:rkac088.
          </a>
         </li>
         <li class="breakAll">
          King TE Jr, Kim EJ, Kinder BW. Connective tissue diseases. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House-USA, Shelton, CT 2011. p.689.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985; 131:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004; 232:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005; 26:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167:1410.
          </a>
         </li>
         <li class="breakAll">
          Colby TV. Lung Pathology. In: The Lung in Rheumatic Diseases, Cannon G, Zimmermann G (Eds), Marcel Dekker, New York 1990. p.145.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest 2006; 130:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013; 107:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin E, Limper AH, Moua T. Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series. BMC Pulm Med 2018; 18:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enomoto Y, Nakamura Y, Colby TV, et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS One 2017; 12:e0180283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvalho J, Vieira AC, Ferra J, et al. Pleuroparenchymal Fibroelastosis in association with Connective Tissue Disease: a new interstitial pneumonia to be aware of. Acta Reumatol Port 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juge PA, Granger B, Debray MP, et al. A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol 2022; 74:1755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matson SM, Deane KD, Peljto AL, et al. Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the MUC5B Promoter Variant. Am J Respir Crit Care Med 2022; 205:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford) 2001; 40:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JW, Chung SW, Pyo JY, et al. Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 2023; 62:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franquet T. High-resolution CT of lung disease related to collagen vascular disease. Radiol Clin North Am 2001; 39:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan WU, Keaney NP, Holland CD, Kelly CA. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994; 193:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 1. Am Rev Respir Dis 1990; 142:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014; 270:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob J, Bartholmai BJ, Rajagopalan S, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J 2017; 49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alevizos MK, Danoff SK, Pappas DA, et al. Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry. Rheumatology (Oxford) 2022; 61:2792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med 1973; 54:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu J, Zhou Y, Chen X, Li J. A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 2014; 41:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HC, Choi KH, Jacob J, Song JW. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. PLoS One 2020; 15:e0229997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maniwa K, Ogushi F, Tani K, et al. Increased incidence of autoantibodies to interleukin-1a in rheumatoid arthritis with interstitial lung disease. Respirology 2000; 5:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Doyle TJ, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2015; 67:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Chen Y, Liu D, et al. Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease. Sci Rep 2022; 12:9469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tishler M, Grief J, Fireman E, et al. Bronchoalveolar lavage--a sensitive tool for early diagnosis of pulmonary involvement in rheumatoid arthritis. J Rheumatol 1986; 13:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popp W, Ritschka L, Scherak O, et al. Bronchoalveolar lavage in rheumatoid arthritis and secondary Sjögren's syndrome. Lung 1990; 168:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez T, Farre JM, Gosset P, et al. Subclinical alveolar inflammation in rheumatoid arthritis: superoxide anion, neutrophil chemotactic activity and fibronectin generation by alveolar macrophages. Eur Respir J 1989; 2:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosset P, Perez T, Lassalle P, et al. Increased TNF-alpha secretion by alveolar macrophages from patients with rheumatoid arthritis. Am Rev Respir Dis 1991; 143:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad JD, Mahar A, Bleasel J, et al. The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology 2017; 22:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Launders N, Martinez F, et al. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res 2019; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014; 43:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008; 26:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoie IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int 2012; 32:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verschueren K, Van Essche E, Verschueren P, et al. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007; 26:1969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol 2010; 16:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 2012; 39:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigne C, Tebib JG, Pacheco Y, Coury F. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 2013; 80:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011; 124:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matson SM, Baqir M, Moua T, et al. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory. Chest 2023; 163:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JW, Lee HK, Lee CK, et al. ﻿Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford) 2019; 58:e3.
          </a>
         </li>
         <li class="breakAll">
          Spanish  Society  of  Rheumatology. Clinical practice guidelines for the management of patients with rheumatoid arthritis. https://www.ser.es/wp-content/uploads/2020/04/Clinical-Practice-Guidelines-for-the-Management-of-Patients-with-Rheumatoid-Arthritis.pdf (Accessed on October 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassone G, Manfredi A, Vacchi C, et al. Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lok SD, Wong AW, Khor YH, et al. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest 2022; 161:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford) 2017; 56:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matteson EL, Bongartz T, Ryu JH, et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheum Autoimmune Dis 2012; 2:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fui A, Bergantini L, Selvi E, et al. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J 2020; 50:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Díaz C, Loricera J, Castañeda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum 2018; 48:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassone G, Manfredi A, Atzeni F, et al. Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurata I, Tsuboi H, Terasaki M, et al. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. Intern Med 2019; 58:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mochizuki T, Ikari K, Yano K, et al. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol 2019; 29:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 2019; 9:e028466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med 2016; 121:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 2008; 168:1718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology 2018; 23:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu Q, Wang L, Li L, et al. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol 2019; 38:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes H, Holland AE, Westall GP, et al. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 2018; 1:CD010908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matteson EL, Kelly C, Distler JHW, et al. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis Rheumatol 2022; 74:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazdani A, Singer LG, Strand V, et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014; 33:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017; 76:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeganathan N, Nguyen E, Sathananthan M. Rheumatoid Arthritis and Associated Interstitial Lung Disease: Mortality Rates and Trends. Ann Am Thorac Soc 2021; 18:1970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010; 49:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011; 37:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol 2017; 69:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yunt ZX, Chung JH, Hobbs S, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respir Med 2017; 126:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki A, Kondoh Y, Brown KK, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020; 25:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon BS, Lee HY, Choe J, et al. Acute Respiratory Deterioration in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study. Chest 2022; 162:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie M, Zhu C, Ye Y. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. BMC Pulm Med 2023; 23:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002; 122:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007; 25:23.
          </a>
         </li>
         <li class="breakAll">
          Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1). NCT02808871. https://www.clinicaltrials.gov/ct2/show/NCT02808871?term=interstitial+lung+disease&amp;cond=rheumatoid+arthritis&amp;rank=4.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredi A, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 2020; 50:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023; 11:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venerito V, Manfredi A, Carletto A, et al. Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study. J Clin Med 2023; 12.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4362 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23460159" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24668537" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Rheumatoid arthritis and lung disease: from mechanisms to a practical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8151583" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cause of death in 81 autopsied patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2169654" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9279235" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Interstitial lung disease in recent onset rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11462065" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227362" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Progressive preclinical interstitial lung disease in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19892679" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20851924" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Rheumatoid arthritis-interstitial lung disease-associated mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33026891" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Autoantibody Seropositivity and Risk for Interstitial Lung Disease in a Prospective Male-Predominant Rheumatoid Arthritis Cohort of U.S. Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30710005" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31089697" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34995017" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20155830" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20444754" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23425964" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Extra-articular rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17657669" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Rheumatoid arthritis treatment and the risk of severe interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24758887" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20217173" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22867979" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34949700" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fine particulate matter components and interstitial lung disease in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33191286" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8843862" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23400887" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23400799" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Developing better biomarkers for connective tissue disease-associated interstitial lung disease: citrullinated hsp90 autoantibodies in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23716070" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23817979" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26768760" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: The spark that lights the fire in rheumatoid arthritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30345907" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34344703" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35289841" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23695349" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34411838" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36382269" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A genome-wide association study identifying single nucleotide polymorphisms in the PPFIBP2 gene was predictive for interstitial lung disease in rheumatoid arthritis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36382269" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A genome-wide association study identifying single nucleotide polymorphisms in the PPFIBP2 gene was predictive for interstitial lung disease in rheumatoid arthritis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15947315" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3873887" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lung biopsy in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8291652" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15166329" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Rheumatoid arthritis-related lung diseases: CT findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15580351" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12615630" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12615630" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899858" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/634315" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Natural history and treated course of usual and desquamative interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23791462" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29929518" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28666014" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31484917" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pleuroparenchymal Fibroelastosis in association with Connective Tissue Disease: a new interstitial pneumonia to be aware of.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36018" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pulmonary involvement in the collagen vascular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35583934" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34874815" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the MUC5B Promoter Variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11561113" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36394143" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11699667" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : High-resolution CT of lung disease related to collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7763110" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7972746" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Lung changes in rheumatoid arthritis: CT findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2240845" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Computed tomography of chronic diffuse infiltrative lung disease. Part 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996193" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24126367" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30487199" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Predicting outcomes in rheumatoid arthritis related interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27811068" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18369202" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Interstitial lung disease in systemic sclerosis: a simple staging system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34747452" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4348718" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24882837" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32163457" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10813282" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11192540" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Increased incidence of autoantibodies to interleukin-1a in rheumatoid arthritis with interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25302945" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Biomarkers of rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35676424" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3735275" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Bronchoalveolar lavage--a sensitive tool for early diagnosis of pulmonary involvement in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2122139" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Bronchoalveolar lavage in rheumatoid arthritis and secondary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2540025" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Subclinical alveolar inflammation in rheumatoid arthritis: superoxide anion, neutrophil chemotactic activity and fibronectin generation by alveolar macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2001072" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Increased TNF-alpha secretion by alveolar macrophages from patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28891101" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30949489" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24231065" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18578973" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20062997" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Development of sarcoidosis following etanercept treatment: a report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17340045" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20808167" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21899592" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22885144" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21531225" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19423648" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513909" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36470416" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22607134" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24071881" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : ﻿Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7740304" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Pulmonary involvement in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30137552" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30137552" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32290218" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23457378" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34921905" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28444364" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30963656" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29422324" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31963908" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30799358" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29798700" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31061059" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27888985" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18695091" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30011421" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30535993" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29297205" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35199968" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34419372" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24630861" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28611082" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33951402" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Rheumatoid Arthritis and Associated Interstitial Lung Disease: Mortality Rates and Trends.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20223814" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20884744" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27788297" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28427540" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26585429" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31426125" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Acute exacerbations of fibrotic interstitial lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35032476" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Acute Respiratory Deterioration in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37434169" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12226061" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17417986" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17417986" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31661185" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36075242" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36769604" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
